Actavis (ACT +1%) reaches a settlement with Shire (SHPG +1.6%) regarding an outstanding patent...
Actavis (ACT +1%) reaches a settlement with Shire (SHPG +1.6%) regarding an outstanding patent litigation related to ACT's generic version of Intuniv, a treatment for ADHD. Under the terms of the settlement, ACT can launch its generic version of Intuniv on December 1, 2014, or earlier under certain circumstances. SHPG will receive a 25% royalty on gross profits from sales during the period of exclusivity.
From other sites
Video at CNBC.com (Sep 21, 2015)
Video at CNBC.com (Aug 6, 2015)
Video at CNBC.com (Jul 27, 2015)
at CNBC.com (Feb 18, 2015)
at CNBC.com (Feb 10, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs